

## First major step in the Immunoscore® reimbursement roadmap

- Immunoscore® is now fully reimbursed by a first Major Private Medical Insurer in the UK

Marseille, France, January 17, 2019: HaliO Dx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that its flagship product, Immunoscore® test, intended to manage therapy decisions in localized colon cancers is now fully reimbursed by a major UK Private Medical Insurer.

Immunoscore® is an in vitro diagnostic test predicting the risk of relapse in early stage colon cancer patients by measuring the host immune response at the tumor site. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information.

*“The reimbursement of Immunoscore® by a major Private Medical Insurer in the UK represents a key milestone for HaliO Dx and is the first step of our reimbursement roadmap and our global market access strategy said” **Vincent Fert President and CEO of HaliO Dx.** He adds “This positive coverage at value-based pricing successfully negotiated by our partner Everything Genetics opens discussions with other private payers and reflects the unique medical utility we are building with Immunoscore® for the benefit of patients and healthcare systems.”*

*“Immunoscore is available for UK patients since July 2018 and the rapid coverage of the test after only 5 months of commercialization clearly shows the undisputable clinical value that this test can bring to oncologists and patients by helping them guiding treatment decisions”. **Added James Price, CEO of Everything Genetic, distributor of the Immunoscore test in the UK.***

\*\*\*

### About HaliO Dx

#### The Immune Response to Cancer Diagnostics

HaliO Dx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information.

Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HaliO Dx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

HaliO Dx has an experienced team of more than 135 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HaliO Dx executes biomarker studies and companion diagnostic assay development in conformity with regulations

and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites [www.haliidx.com](http://www.haliidx.com) and [www.immunoscore-colon.com](http://www.immunoscore-colon.com) and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

## Contacts

### **HalioDx SAS**

#### **Vincent Fert**

President and CEO

+ 33 (0)4 91 29 30 90

[vincent.fert@haliidx.com](mailto:vincent.fert@haliidx.com)

### **Everything Genetic Ltd**

#### **James Price**

CEO and Founder

+44 (0) 1270 623 179

[info@everythinggeneticltd.co.uk](mailto:info@everythinggeneticltd.co.uk)

[www.everythinggeneticltd.co.uk](http://www.everythinggeneticltd.co.uk)

### **ATCG Press**

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

[haliidx@atcg-partners.com](mailto:haliidx@atcg-partners.com)

[Twitter: twitter.com/haliidx](https://twitter.com/haliidx)